Key Points
- Rejoni showcased its FDA-approved Juveena Hydrogel System at the AAGL 55th Global Congress on Minimally Invasive Gynecologic Surgery in Boston.
- The system is designed to reduce intrauterine adhesion formation following hysteroscopic adhesiolysis.
- Clinical trial results published in Fertility and Sterility showed that 60.3% of participants who received the hydrogel barrier were adhesion-free at second-look hysteroscopy.
What is the Juveena Hydrogel System and How Does it Work?
Rejoni, Inc., a commercial-stage women's health company, has showcased its FDA-approved Juveena Hydrogel System at the AAGL 55th Global Congress on Minimally Invasive Gynecologic Surgery in Boston. The system is designed to reduce intrauterine adhesion formation following hysteroscopic adhesiolysis, a common complication of uterine surgery.
Intrauterine adhesions, also known as Asherman syndrome, can lead to menstrual abnormalities, pregnancy loss, and infertility. The Juveena Hydrogel System uses a proprietary transcervical catheter to deliver two aqueous polymer solutions that rapidly form a soft, temporary hydrogel spacer. This spacer keeps the uterine walls apart while they heal, reducing the risk of adhesions.
At a Glance
| Main Company | Rejoni, Inc. Commercial-stage women's health company |
| Main Executive | John Nealon Chief Executive Officer |
| Organization | AAGL 55th Global Congress on Minimally Invasive Gynecologic Surgery Medical conference |
| Regulator | FDA US Food and Drug Administration |
| Location | Boston City and conference venue |
Behind the FDA Approval and Clinical Trial Results
Behind the FDA Approval and Clinical Trial Results
The Juveena Hydrogel System received FDA premarket approval in September 2026, after a randomized, blinded trial showed that 60.3% of participants who received the hydrogel barrier were adhesion-free at second-look hysteroscopy. The trial, published in Fertility and Sterility, was conducted across 15 U.S. academic and community gynecologic surgery centers and involved 150 participants.
The results were accompanied by an independent editorial commentary, which highlighted the trial's rigorous design and the potential benefits of the Juveena Hydrogel System for women's health.
What Does this Mean for Women's Health and Future Research?
What Does this Mean for Women's Health and Future Research?
The FDA approval of the Juveena Hydrogel System is an important milestone for Rejoni and the women's health community. The system has the potential to reduce intrauterine adhesion formation and improve outcomes for women undergoing uterine surgery.
Future research should focus on further evaluating the efficacy and safety of the Juveena Hydrogel System in larger, more diverse populations. Additionally, researchers should explore the potential applications of the system in other areas of women's health.
Comments 0